covid 19 News and Research

RSS
Severe COVID-19 may result in premature aging in recovered patients

Severe COVID-19 may result in premature aging in recovered patients

Study suggests making COVID vaccines based on Mu variant

Study suggests making COVID vaccines based on Mu variant

COVID vaccines effectively reduce outbreaks of SARS-CoV-2 alpha and delta viruses in households

COVID vaccines effectively reduce outbreaks of SARS-CoV-2 alpha and delta viruses in households

Identifying the spread of novel B.1.1.523 SARS-CoV-2

Identifying the spread of novel B.1.1.523 SARS-CoV-2

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

Study shows plasmacytoid dendritic cells may be a viable target for protection against SARS-CoV-2

An analysis of SARS-CoV-2 breakthrough infections by variant and vaccine

An analysis of SARS-CoV-2 breakthrough infections by variant and vaccine

Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients

Study finds no evidence to support favipiravir use in mild or asymptomatic COVID-19 patients

Low neutralizing antibody titers against SARS-CoV-2 Mu in BNT162b2 vaccinated

Low neutralizing antibody titers against SARS-CoV-2 Mu in BNT162b2 vaccinated

Using dried blood spots to monitor SARS-CoV-2 antibodies at home

Using dried blood spots to monitor SARS-CoV-2 antibodies at home

How often does SARS-CoV-2 infect alongside another viruses?

How often does SARS-CoV-2 infect alongside another viruses?

The introduction and rapid spread of SARS-CoV-2 Gamma in Venezuela

The introduction and rapid spread of SARS-CoV-2 Gamma in Venezuela

Vaccination provides full protection against severe outcomes of COVID-19 among U.S. Coast Guard

Vaccination provides full protection against severe outcomes of COVID-19 among U.S. Coast Guard

Seroprevalence study reveals high exposure to SARS-CoV-2 in Bangui population

Seroprevalence study reveals high exposure to SARS-CoV-2 in Bangui population

SARS-CoV-2 Omicron variant: What we know so far

SARS-CoV-2 Omicron variant: What we know so far

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

Complex RNA structures could have untapped therapeutic potential in the fight against COVID-19

Genetic ancestry can explain population-level differences in immune response to the flu virus

Genetic ancestry can explain population-level differences in immune response to the flu virus

Viral RNA in the blood found to be a reliable indicator of COVID-19 mortality risk

Viral RNA in the blood found to be a reliable indicator of COVID-19 mortality risk

Tech platforms launch new interactive features to help boost vaccine uptake

Tech platforms launch new interactive features to help boost vaccine uptake

WHO designates Omicron (B.1.1.529) as SARS-CoV-2 Variant of Concern

WHO designates Omicron (B.1.1.529) as SARS-CoV-2 Variant of Concern

Prediction of severe infection based on SARS-CoV-2 genomic analysis

Prediction of severe infection based on SARS-CoV-2 genomic analysis

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.